Eris Lifesciences Ltd (NSE: ERIS, BSE: 540596) is an Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹17,691 Cr, it ranks #400 by market cap among the 6,197 Indian listed companies on FinBizNet, and #8 of 63 in Pharmaceuticals. At ₹1,309.00 (as of 16 Nov 2026), the share price is 24.8% below its 52-week high of ₹1,740.00 and 22.5% above its 52-week low of ₹1,069.00. The share price is down 17.5% over one year and down 5.3% over three months.
| Current Price | ₹1,309.00 |
|---|---|
| Market Cap | ₹17,691 Cr |
| NSE Symbol | ERIS |
| BSE Code | 540596 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 28.3 |
| Return on Equity | 18.07% |
| Return on Assets | 7.30% |
| 52-Week Range | ₹1,069.00 – ₹1,740.00 |
| 1-Year Price Change | -17.5% |
| 3-Month Price Change | -5.3% |
| Beta (1Y) | -0.01 |
| Dividend Yield | 1.13% |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.eris.co.in |
| Revenue | ₹892 Cr |
|---|---|
| Net Profit | ₹187 Cr |
| Net Margin | 21.0% |
| EPS (Basic) | ₹13.26 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Eris Lifesciences Ltd reported revenue of ₹892 Cr in Q2 FY27, up 12.6% from ₹792 Cr in Q2 FY26 and up 2.2% from ₹873 Cr in Q1 FY27. It posted a net profit of ₹187 Cr for the quarter, against a net profit of ₹134 Cr in Q2 FY26 (up 39.2%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹705 Cr (Q4 FY25) to ₹892 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹892 Cr | ₹187 Cr | 21.0% |
| Q1 FY27 | ₹873 Cr | ₹143 Cr | 16.4% |
| Q4 FY26 | ₹757 Cr | ₹279 Cr | 36.9% |
| Q3 FY26 | ₹807 Cr | ₹109 Cr | 13.5% |
| Q2 FY26 | ₹792 Cr | ₹134 Cr | 17.0% |
| Q1 FY26 | ₹773 Cr | ₹125 Cr | 16.2% |
| Q4 FY25 | ₹705 Cr | ₹102 Cr | 14.5% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 54.74% of Eris Lifesciences Ltd's shares as of Sept 2026, against 54.85% in Sept 2025 (−0.11 percentage points). Delivery averaged 52.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.
1. Pharmaceuticals-This segment develops, manufactures, and commercializes pharmaceutical products in chronic and acute therapeutic areas.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Astrazeneca Pharma India Ltd. | ₹16,078 Cr | 85.9 | 22.82% | ₹729 Cr | -34.3% |
Listed by market capitalisation. Ratios are shown for context only.
Eris Lifesciences Ltd is trading at ₹1,309.00, with a market capitalisation of ₹17,691 Cr.
Eris Lifesciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Eris Lifesciences Ltd has a P/E of 28.3 and a return on equity of 18.07%.
Eris Lifesciences Ltd is listed on the NSE under the symbol ERIS and on the BSE under the scrip code 540596.
Eris Lifesciences Ltd's share price is down 17.5% over one year and down 5.3% over three months. Its 52-week range is ₹1,069.00 to ₹1,740.00.
In Q2 FY27, Eris Lifesciences Ltd reported revenue of ₹892 Cr and net profit of ₹187 Cr, with basic EPS of ₹13.26 (consolidated, parsed from the company's exchange filing).
Eris Lifesciences Ltd reported revenue of ₹892 Cr in Q2 FY27, up 12.6% from ₹792 Cr in Q2 FY26 and up 2.2% from ₹873 Cr in Q1 FY27.
Promoters held 54.74% of Eris Lifesciences Ltd's shares as of Sept 2026, against 54.85% in Sept 2025 (−0.11 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.